无并发症单菌肠球菌血流感染的抗生素疗程:多中心目标试验模拟
该研究采用目标试验模拟框架,在以色列8家医院回顾性纳入485例无并发症单菌肠球菌血流感染成人患者,比较短疗程(7±2天)与长疗程(14±2天)抗生素治疗。调整分析显示两组30天死亡率无差异(21.6% vs 21.3%;aRR 1.01,95%CI 0.84-1.22),次要结局亦无差异,支持在合适患者中采用短疗程。
要点
- 无并发症单菌肠球菌血流感染短疗程与长疗程30天死亡率无差异。
- 短疗程组30天死亡21.6%,长疗程组21.3%,aRR 1.01(95%CI 0.84-1.22)。
- 次要结局(90天死亡、复发、住院时间、再入院、艰难梭菌感染)均无差异。
核心结论
- 在无并发症单菌肠球菌血流感染成人患者中,短疗程抗生素治疗与长疗程相比临床结局相当,支持在适当选择患者中使用短疗程。
研究设计与样本
- 回顾性队列研究,采用目标试验模拟框架,纳入以色列8家医院2013-2023年成人无并发症单菌肠球菌血流感染住院患者。
- 筛查3450例肠球菌菌血症患者,870例符合条件,485例接受符合研究策略的疗程(短疗程n=283,长疗程n=202)。
- 短疗程定义为7±2天,长疗程定义为14±2天;采用克隆-删失-加权框架及逆概率删失权重处理永恒时间偏倚和混杂。
主要发现
- 485例患者平均年龄74岁(±15.0);87/485(18%)有预先存在的心脏植入装置,164/485(34%)为尿路来源,180/485(37%)为医院获得性血流感染。
- 调整分析显示短疗程与长疗程30天死亡率无差异(21.6% vs 21.3%;调整风险比1.01,95%CI 0.84-1.22)。
- 次要结局(90天全因死亡率、复发、住院时间、再入院和艰难梭菌感染)均无差异证据。
- 亚组和敏感性分析结果一致。
临床怎么用
- 对于 appropriately selected 无并发症单菌肠球菌血流感染患者,可考虑短疗程(7±2天)抗生素治疗。
- 临床决策需结合患者个体情况,参考本研究纳入标准选择合适患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Enterococcal bloodstream infection (BSI) is common with 30-day mortality rates approaching 25%-30%, yet evidence guiding optimal antibiotic treatment duration, particularly for patients with uncomplicated infection, is limited. METHODS: We conducted a retrospective cohort study using a target trial emulation framework across 8 hospitals in Israel (2013-2023) of adults hospitalized with uncomplicated monomicrobial enterococcal BSI. Treatment strategies were defined as short (7 ± 2 days) versus long (14 ± 2 days) antibiotic therapy. A cloning-censoring-weighting framework with inverse probability of censoring weights was applied to account for immortal time bias and potential confounders. The primary outcome was 30-day all-cause mortality; secondary outcomes included 90-day all-cause mortality, recurrence, length of stay, readmission and Clostridioides difficile infection. Analyses were performed using pooled logistic regression and negative binomial regression models, with prespecified subgroup and sensitivity analyses. RESULTS: Of 3450 patients with enterococcal bacteremia screened, 870 were eligible, and 485 received treatment durations consistent with the study treatment strategies (short n = 283, long n = 202). Mean age was 74 years (±15.0); 87/485 (18%) had pre-existing cardiac hardware, 164/485 (34%) a urinary source and 180/485 (37%) had nosocomial BSI. Adjusted analyses demonstrated no difference in 30-day mortality between short and long therapy (21.6% vs 21.3%; adjusted risk ratio 1.01, 95% CI 0.84 to 1.22). There was no evidence of differences across the secondary outcomes. Results were consistent across subgroup and sensitivity analyses. CONCLUSIONS: Short-course antibiotic treatment was associated with comparable clinical outcomes to long-course treatment in uncomplicated monomicrobial enterococcal BSI, supporting the use of short treatment durations in appropriately selected patients.
引用
- Mudrik-Zohar H, Ong SWX, Tong SYC, et al. Antibiotic Treatment Duration for Uncomplicated Monomicrobial Enterococcal Bloodstream Infection: A Multicenter Target Trial Emulation. Clin Infect Dis. 2026. PMID: 42397386. doi:10.1093/cid/ciag387
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。